Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025
Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has announced its upcoming participation at The Citizens Life Sciences Conference.
The company's management will deliver a presentation on Wednesday, May 7, 2025, at 12:30 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the "Events" section of Sionna's investor relations website at investors.sionnatx.com.
Sionna's mission centers on revolutionizing CF treatment by developing new medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The presentation recording will remain accessible on the company's website for 90 days following the event.
Sionna Therapeutics (Nasdaq: SION), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti per la fibrosi cistica (CF), ha annunciato la sua prossima partecipazione alla Citizens Life Sciences Conference.
Il management dell'azienda terrà una presentazione mercoledì 7 maggio 2025 alle 12:30 ET. Investitori e interessati potranno seguire la diretta streaming della presentazione tramite la sezione "Eventi" del sito web dedicato agli investitori di Sionna all'indirizzo investors.sionnatx.com.
La missione di Sionna è rivoluzionare il trattamento della fibrosi cistica sviluppando nuovi farmaci che normalizzano la funzione della proteina regolatrice della conduttanza transmembrana della fibrosi cistica (CFTR). La registrazione della presentazione resterà disponibile sul sito web aziendale per 90 giorni dopo l'evento.
Sionna Therapeutics (Nasdaq: SION), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar tratamientos para la fibrosis quística (FQ), ha anunciado su próxima participación en la Citizens Life Sciences Conference.
La dirección de la empresa realizará una presentación el miércoles 7 de mayo de 2025 a las 12:30 p.m. ET. Inversores e interesados podrán acceder a una transmisión en vivo de la presentación a través de la sección "Eventos" del sitio web de relaciones con inversores de Sionna en investors.sionnatx.com.
La misión de Sionna se centra en revolucionar el tratamiento de la fibrosis quística desarrollando nuevos medicamentos que normalicen la función de la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR). La grabación de la presentación estará disponible en el sitio web de la empresa durante 90 días después del evento.
Sionna Therapeutics (나스닥: SION)는 낭포성 섬유증(CF) 치료제 개발에 집중하는 임상 단계 바이오제약 회사로, Citizens Life Sciences Conference에 참여할 예정임을 발표했습니다.
회사의 경영진은 2025년 5월 7일 수요일 오후 12시 30분(동부 시간)에 발표를 진행할 예정입니다. 투자자 및 관심 있는 분들은 Sionna 투자자 관계 웹사이트의 "Events" 섹션에서 라이브 웹캐스트를 시청할 수 있습니다(주소: investors.sionnatx.com).
Sionna의 사명은 낭포성 섬유증 막단백질 조절자(CFTR) 단백질의 기능을 정상화하는 새로운 약물을 개발하여 CF 치료 방식을 혁신하는 데 집중하고 있습니다. 발표 녹화 영상은 행사 후 90일 동안 회사 웹사이트에서 계속 시청할 수 있습니다.
Sionna Therapeutics (Nasdaq : SION), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements pour la fibrose kystique (FK), a annoncé sa prochaine participation à la Citizens Life Sciences Conference.
La direction de l'entreprise présentera le mercredi 7 mai 2025 à 12h30 ET. Les investisseurs et les personnes intéressées pourront suivre la diffusion en direct de la présentation via la section "Événements" du site web des relations investisseurs de Sionna à l'adresse investors.sionnatx.com.
La mission de Sionna est de révolutionner le traitement de la fibrose kystique en développant de nouveaux médicaments qui normalisent la fonction de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique (CFTR). L'enregistrement de la présentation restera accessible sur le site web de l'entreprise pendant 90 jours après l'événement.
Sionna Therapeutics (Nasdaq: SION), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Behandlungen für zystische Fibrose (CF) spezialisiert hat, hat seine bevorstehende Teilnahme an der Citizens Life Sciences Conference angekündigt.
Das Management des Unternehmens wird am Mittwoch, den 7. Mai 2025, um 12:30 Uhr ET eine Präsentation halten. Investoren und Interessierte können die Live-Übertragung der Präsentation über den Bereich "Events" auf der Investor-Relations-Website von Sionna unter investors.sionnatx.com verfolgen.
Die Mission von Sionna besteht darin, die Behandlung von CF zu revolutionieren, indem neue Medikamente entwickelt werden, die die Funktion des cystischen Fibrose-Transmembranleitfähigkeitsregulators (CFTR-Proteins) normalisieren. Die Aufzeichnung der Präsentation wird für 90 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- Clinical-stage biotech company with focus on cystic fibrosis treatment innovation
- Development of novel CFTR protein-targeting medicines indicates potential market opportunity
- None.
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 12:30 p.m. ET.
A live webcast of the presentation will be available the day of the event on the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will be available for 90 days following the event.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
FAQ
When will Sionna Therapeutics (SION) present at The Citizens Life Sciences Conference 2025?
How can I watch Sionna Therapeutics' (SION) presentation at the Citizens Conference 2025?
What is Sionna Therapeutics' (SION) main focus in cystic fibrosis treatment?
How long will Sionna Therapeutics' (SION) May 2025 conference presentation replay be available?
What stage is Sionna Therapeutics (SION) at in developing CF treatments?
